COMT and chronic myelogenous leukemia, BCR-ABL1 positive: Clinical trials using nilotinib, a TKI previously used as a treatment for chronic myelogenous leukemia, identified significantly altered microRNAs (miRNAs) that targeted various neurotransmitter-associated genes, including catechol-O-methyltransferase (COMT), aldehyde dehydrogenases (ALDHs), and sulferotransferases (SULTs) (Anderson et al., 2022; Stevenson et al., 2023).